Back to search
FDAFDA · Food and drugs·Recall number D-0474-2023

Dofetilide Capsules, 500 mcg (0.5 mg), 60-count bottle, Rx only, Manufactured by: Sun Pharmaceutical Industries Limited, Survey No. 259/15, Dadra-396 191, (U.T. of D & NH), India, NDC 47335-0063-86

Published March 29, 2023 · Recall initiated: March 9, 2023

Summary

FDA records drug Class III recall D-0474-2023, published March 29, 2023 and initiated March 9, 2023. Recalling firm: SUN PHARMACEUTICAL INDUSTRIES INC; Status: Terminated; Reported quantity: 1,920 bottles; Lot: Lot # DND1541A, Exp 08/2024. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Content Uniformity Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
SUN PHARMACEUTICAL INDUSTRIES INC
Distributor
USA nationwide.
Lot
Lot # DND1541A, Exp 08/2024
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Dofetilide Capsules, 500 mcg (0.5 mg), 60-count bottle, Rx only, Manufactured by: Sun Pharmaceutical Industries Limited, Survey No. 259/15, Dadra-396 191, (U.T. of D & NH), India, NDC 47335-0063-86 recalled?

Yes. FDA published recall D-0474-2023 on March 29, 2023. Reported hazard: Failed Content Uniformity Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter